Q1 2024 · 13F-HR
Logos Global Management LPholdings as filed
Filed 2024-05-15 · accession 0001172661-24-002503
$1.24B
Reported value
57
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $155.4M | 12.6% | 1,200,000 | CALL | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $74.7M | 6.05% | 500,000 | CALL | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $65.8M | 5.33% | 1,500,000 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $58.5M | 4.73% | 900,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $57.4M | 4.64% | 1,775,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $52.0M | 4.21% | 5,811,436 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $51.8M | 4.19% | 400,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $49.6M | 4.02% | 4,383,875 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $49.1M | 3.98% | 1,730,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $47.0M | 3.81% | 800,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $35.0M | 2.83% | 1,300,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $31.1M | 2.52% | 1,476,061 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $30.9M | 2.50% | 720,058 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $29.7M | 2.40% | 9,000,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $27.3M | 2.21% | 650,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $26.4M | 2.14% | 1,574,220 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $24.8M | 2.01% | 575,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $21.9M | 1.77% | 3,050,000 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $21.2M | 1.72% | 1,499,999 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $20.3M | 1.64% | 5,032,501 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $20.2M | 1.64% | 800,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $19.3M | 1.56% | 450,000 | CALL | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $17.5M | 1.42% | 1,244,960 | Common | SOLE |
| 23256X100 | — | CYBIN INC | $16.5M | 1.34% | 40,000,000 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $14.4M | 1.16% | 650,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $14.1M | 1.14% | 1,000,000 | CALL | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $13.2M | 1.07% | 300,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $12.9M | 1.04% | 800,000 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $12.4M | 1.01% | 500,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $12.3M | 0.99% | 700,000 | Common | SOLE |
| 230031106 | CGEM | CULLINAN ONCOLOGY INC | $11.9M | 0.97% | 700,000 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $10.5M | 0.85% | 1,000,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $9.5M | 0.77% | 250,000 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $9.4M | 0.76% | 1,000,000 | CALL | SOLE |
| 53566P109 | LCTX | LINEAGE CELL THERAPEUTICS IN | $9.3M | 0.75% | 6,250,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $9.2M | 0.74% | 150,000 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $9.0M | 0.73% | 1,350,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $8.3M | 0.67% | 350,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $7.6M | 0.61% | 2,200,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $7.2M | 0.58% | 1,000,000 | CALL | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $7.0M | 0.57% | 100,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $6.4M | 0.52% | 300,000 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $6.2M | 0.50% | 382,345 | Common | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $6.0M | 0.49% | 3,100,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $5.6M | 0.46% | 150,000 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $5.3M | 0.43% | 700,000 | CALL | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $5.1M | 0.42% | 1,000,000 | Common | SOLE |
| 65343E108 | NXTCEUR | NEXTCURE INC | $4.3M | 0.35% | 1,925,000 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $3.7M | 0.30% | 2,900,000 | Common | SOLE |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $3.0M | 0.24% | 3,469,927 | Common | SOLE |
| 10170A100 | BOLD | BOUNDLESS BIO INC | $2.9M | 0.23% | 200,000 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $2.3M | 0.18% | 99,208 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $1.8M | 0.15% | 257,980 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $854,321 | 0.07% | 493,827 | Common | SOLE |
| 4525EP101 | VTLUSD | IMMUNIC INC | $555,963 | 0.04% | 421,184 | Common | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $105,070 | 0.01% | 39,500 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $22,743 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.